Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
oxcarbazepine · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| oxcarbazepine | DRUG | - |
INCLUSION CRITERIA: To enter this study, patients must: * Have a diagnosis of partial seizures * Have 2-30 seizures per week while on a stable dose of one anti-epileptic drug or be a patient recently diagnosed with partial seizures and currently receiving no seizure medication * Be willing to be ho...
Oxcarbazepine is used for the treatment of epilepsy. It is a small molecule developed by Novartis AG (NYSE: NVS) and is currently in Phase 3 clinical development for this indication. The drug is being studied in pediatric populations with epilepsy, including partial epilepsies.
Oxcarbazepine is developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is being investigated for the treatment of epilepsy and is currently in Phase 3 clinical trials.
Oxcarbazepine is in Phase 3 clinical development for epilepsy. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total of 226 participants enrolled across multiple countries.
Oxcarbazepine has been studied in two completed Phase 3 clinical trials: NCT00050934 and NCT00050947, both titled 'Pediatric Epilepsy Study'. These trials enrolled 132 and 94 participants respectively, including children as young as 1 month old, across the United States, Brazil, Germany, and Mexico.
Oxcarbazepine is not FDA approved for the indication being studied. It is currently in Phase 3 clinical development, with two completed trials in pediatric epilepsy. The drug remains investigational and has not received regulatory approval for this use.